Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/41—Porphyrin- or corrin-ring-containing peptides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/002—Protozoa antigens
  • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/02—Bacterial antigens
  • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/12—Viral antigens
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
  • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
  • A61K47/544—Phospholipids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
  • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
  • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
  • A61P31/18—Antivirals for RNA viruses for HIV
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
  • A61K2039/55511—Organic adjuvants
  • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
  • A61K2039/55511—Organic adjuvants
  • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
  • A61K2039/55588—Adjuvants of undefined constitution
  • A61K2039/55594—Adjuvants of undefined constitution from bacteria
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2740/00—Reverse transcribing RNA viruses
  • C12N2740/00011—Details
  • C12N2740/10011—Retroviridae
  • C12N2740/16011—Human Immunodeficiency Virus, HIV
  • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
  • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
  • C12N2760/00011—Details
  • C12N2760/18011—Paramyxoviridae
  • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
  • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Definitions

• This disclosure relates general to the field of functionalized nanostructures.
• the disclosure relates to nanostructures comprising cobalt-porphyrin.
• Bioconjugate chemistry has provided a range of strategies, but most nanoparticulate conjugations suffer from limitations relating to one or more of the following: 1) low conjugation yields and necessitated purification steps; 2) incompatibility with biological buffers, making labeling of intact nanoparticles impossible; 3) variable labeling sites and conjugated polypeptide conformations, creating an inhomogeneous particle population of varying efficacy; 4) necessity for complex and exogenous chemical approaches.
• Another approach that is suitable for smaller peptides which are less prone to permanent denaturation in organic solvents is to conjugate the peptides to a lipid anchor.
• the resulting lipopeptides can then be incorporated along with the other lipids during the liposome formation process.
• This approach has been used to generate synthetic vaccines that induce antibody production against otherwise non-immunogenic peptides.
• due to their amphipathic character in that case the lipopeptides were difficult to purify, with a yield of 5-10%. It has also been shown that lipopeptides do not fully incorporate into liposomes during the formation process, resulting in aggregation.
• the present disclosure provides functionalized nanostructures.
• the nanostructures can be used for delivery of cargo, targeted delivery and/or delivery of presentation molecules.
• the nanostructures can be monolayers or bilayers which enclose an aqueous compartment therein. Bilayer structures enclosing an aqueous compartment are referred to herein as liposomes.
• the nanostructures can be monolayer or bilayer coating on a nanoparticle.
• the monolayer or bilayer comprises cobalt porphyrin-phospholipid conjugate, optionally phospholipids that are not conjugated to porphyrin, optionally sterols, and optionally polyethylene glycol (PEG).
• One or more targeting peptides or polypeptides (referred to herein as presentation molecules) having a polyhistidine tag are incorporated into the monolayer or bilayer such that a portion of the polyhistidine tag resides in the monolayer or bilayer and the presentation molecule is exposed to the exterior of the monolayer or bilayer.
• presentation molecules targeting peptides or polypeptides having a polyhistidine tag
• cobalt porphyrin can be used.
• the nanostructures of the present disclosure can be loaded with cargo for delivery to sites that can be targeted by the polyhistidine tagged presentation molecules.
• liposomes can be loaded with cargo for delivery to desired sites by using polyhistidine tagged presentation molecules.
• a bilayer containing a cobalt-porphyrin such as a cobalt porphyrin-phospholipid (CoPoP) can stably bind polyhistidine-tagged (also referred to herein as“his-tagged”) polypeptides (Fig. la).
• Other metallo-porphyrins such as zinc, nickel, and copper are not able to stably bind a his-tagged polypeptide.
• lipid bilayers containing porphyin-phospholipid which is chelated with cobalt, but not other metals can effectively capture his-tagged proteins and peptides.
• the binding follows a Co(II) to Co(III) transition and occurs within the sheltered hydrophobic bilayer, resulting in, for example, essentially irreversible attachment in serum or in million-fold excess of competing imidazole.
• homing peptides into the bilayer of pre-formed empty and cargo-loaded liposomes to enable site targeting (such as tumor-targeting) without disrupting the bilayer integrity.
• Peptides or synthetic peptide can be bound to liposomes containing an adjuvant (such as the lipid monophosphoryl lipid A) for antibody generation for an otherwise non-antigenic peptides.
• the present disclosure provides monolayer or bilayer structures, wherein the monolayer or bilayer comprises porphyrins with cobalt chelated thereto such that the cobalt metal resides within monolayer or bilayer and the porphyrin macrocycle and further has molecules with a histidine tag non-covalently attached thereto, such that at least a part of the his-tag is within the monolayer or bilayer and coordinated to the cobalt metal core.
• the presentation molecules can be used for various applications including targeting and generation of immune responses. Liposomes or micelles formed by the present layers may be loaded with cargo for release at desired locations.
• the cobalt porphyrin maybe be cobalt porphyrin-phospholipid (CoPoP).
• the present layers may also be used as coatings for other nanostructures including metal nanoparticles, nanotubes and the like.
• FIG. 1 His-tag binding to PoP -bilayers
• a Schematic showing a peptide with a His-tag (green) binding to pre-formed CoPoP liposomes in aqueous solution
• b Insertion of a His-tagged polypeptide into a bilayer containing CoPoP. Only a single leaflet of the bilayer is shown
• c Chemical structure of metallo-PoPs used in this study.
• FIG. 1 His-tagged protein binding to Co(III)-PoP liposomes
• a heptahis- tagged fluorescence protein comprising Cerulean (C) fused to Venus (V) reveals binding to PoP -bilayers. When C is excited, FRET occurs and V emits fluorescence (left), but this is inhibited when bound to the PoP -bilayer due to competing FRET with the photonic bilayer (middle).
• left to right are bars for: CoPoP and 2H-PoP (e) Reversal of His-tagged peptide binding to CoPoP liposomes following addition of 2 M sodium sulfate. Liposomes were formed with 10 molar % CoPoP or Ni-NTA phospholipid. For each set of bars, the bars from left to right are: water, and +2M sulfite.
• FIG. 1 RGD-His targeting of cargo-loaded liposomes
• B ALB/c or athymic nude mice were immunized with CoPoP liposomes containing a 25 pg of MPL and 25 pg of His-tagged MPER peptide derived from the HIV gp41 envelope protein.
• Sera titer was assessed with an ELISA using a biotinylated MPER peptide lacking a His-tag and probed with an anti-IgG secondary antibody.
• Figure 8 Stable his-tagged protein binding to liposomes containing CoPoP.
• the reporter protein was incubated with liposomes containing CoPoP, free Co-porphyrin or 2H-PoP, then incubated in serum and subjected to EMSA.
• the protein was then imaged using the FRET channel (ex: 430 nm, em: 525 nm).
• the lack of signal in the CoPoP lane demonstrates stable binding to the liposomes.
• the diminished signal in the Co-porphyrin lane demonstrates some binding of the his-tagged protein to the liposomes.
• Figure 9 Time for 90 % peptide binding of RGD-His to CoPoP liposomes of different compositions. Effect of liposome composition on the time for 90 % peptide binding to CoPoP liposomes (10 molar % CoPoP), containing the indicated components when incubated in PBS with the RGD-His peptide. For each set of bars, the bars from left to right are: + cholesterol, and - cholesterol.
• FIG. 10 RGD-His binding to CoPoP liposomes in the presence of serum or albumin. Liposomes of the indicated composition were incubated with the RGD-his peptide in the presence of 50% fetal bovine serum or 50 mg/mL bovine serum albumin. The FAM- labeled peptide emission was normalized by comparing the peptide emission when bound to CoPoP liposomes to 2H-PoP liposomes.
• FIG. 11 Membrane permeabilization by lipopeptides. Sulforhodamine B loaded liposomes were incubated with the indicated peptides (5 pg/mL) at room temperature and release was assessed using fluorescence. For each set of bars, the bars from left to right are: 8 hr, and 24 hr.
• CoPoP and cell targeting (a) Normalized peptide fluorescence upon incubation with CoPoP liposomes containing 1 molar % CoPoP. Emission was normalized by comparing CoPoP samples with 2H-PoP. (b) Cell uptake of sulforhodamine B liposomes containing 1 molar % CoPoP, incubated with cells as indicated. For each set of bars, the bars from left to right are: MCF7 cells, and U87 cells.
• FIG. 14 (A) Psf25 (Pfs25_B) binding was measured by a centrifugal filtration assay. These data indicate 100% binding of the Psf25 protein to Co-pop liposomes. (B) Particle size of CoPoP liposomes before and after Psf25 protein binding.
• FIG. 15 Anti-Psf25 IgG levels in CD-I mice. Mice were vaccinated with
• Psf25 in CoPoP/MPL or ISA70 following intramuscular injections with (A) pre-boost and (B) after boost, three-week prime/three-week boost (5, 0.5 or 0.05 ug Pfs25 per injection).
• Figure 17 Illustration and characterization of different length of NANP peptide coating on CoPoP liposomes.
• A Different numbers of NANP repeated peptide containing 7x histidine (His) tag.
• FIG. 19 Fluorescence of U87 cells following incubation with CoPoP liposomes bound to various his-tagged CPPs.
• Figure 20 After incubating at room temperature for 2 hours, DS-Cavl bearing a his-tag achieved near complete binding with CoPoP nanoparticles (Figure 20, left). His- tagged DS-Cavl did not bind significantly to PoP particles lacking cobalt (2HPoP), and DS- Cavl without the his-tag present did not achieve significant binding with either particle. His- tagged DS-Cavl did not induce liposome aggregation upon binding based on liposome diameter ( Figure 20, center) or polydispersity (Figure 20, right).
• FIG. 21 CoPoP/DS-Cavl vaccination results in higher IgG antibody titer both before and after booster injections. At 35 days post-primary injection, CoPoP vaccine achieves the greatest RSV neutralization.
• CD-I mice were intramuscularly injected with 100 ng DS-Cavl on day 0 and day 21 and serum was collected on day 42 and assessed for neutralization.
• CoPoP/PHAD liposomes (A) Optimum binding mass ratio of OspA:CoPoP/PHAD liposomes evaluated by native PAGE (histidine-MOPS buffer system pH 6.8). (B) Kinetics of OspA binding to CoPoP/PHAD liposomes incubated at 1 :4 mass ratio at room temperature. (C) Specific binding of his-tagged OspA to CoPoP/PHAD liposomes measured by microBCA assay of supernatant obtained from high-speed centrifugation of liposomes. (D)
• Figure 24 Assessing epitope availability and stability of antigen- functionalized nanoliposomes.
• A Stability of nanoliposome-antigen particles in 20% (v/v) human serum based on fluorescence quenching assay.
• B Immunoprecipitation of OspA- bound liposomes by OspA-specific monoclonal antibody LA-2.
• FIG. 25 Evaluation of the immunogenicity of OspA-based nanoliposomal vaccine.
• A Anti-OspA IgG titers induced by CoPoP/PHAD liposomes compared to other commercial adjuvants. Detection of anti-OspA IgG antibodies by (B) indirect
• FIG. 26 Thl-biased immune response of OspA-bound CoPoP/PHAD liposomes.
• A IgG isotype profiling for post-immune sera (day 42) using ELISA.
• FIG. 27 Assessment of the borreliacidal activity of SNAP-induced OspA antibodies.
• A Serum bactericidal antibody assay performed using guinea pig complement. Survival percentage was derived from normalization of the number of spirochetes after overnight serum treatment to that immediately after incubation. Surviving B. burgdorferi B31-A3 were counted using dark-field microscopy.
• B Average 50% borreliacidal activity (serum dilution rate that effectively eliminated 50% of the bacteria) from three different mice sera. Error bars represent standard error of the mean. NI stands for no inhibition. Statistical significance (p ⁇ 0.05, indicated by asterisks) of differences between bactericidal titers is assessed by Kruskal -Wallis test with Dunn’s post-hoc.
• Figure 28 Longevity of anti-OspA IgG levels in SNAP-immunized mice.
• Endpoint titer is defined as the reciprocal of serum dilution at absorbance cut-off value of 0.5. Data points represent geometric mean and the error bars the 95% confidence interval.
• H3 antigen Frl478 (from flu strain A/canine/Illinois/11613/2015) adjuvated with CoPoP/MPLA, 2HPoP/MPLA, or Alum (aluminum hydroxide), and then inoculated with A/Hong Kong/1/1968.
• A The IgG ELISA and
• B HAI assays performed with serum samples taken throughout the vaccination period show that CoPoP/MPLA+Frl478 particles achieve the best antibody response prior to viral challenge.
• C-D Body weight remained stable across the 8-day challenge period, and both (E) viral load and (F) white blood cell count in lung tissue were minimal in CoPoP vaccinated mice, indicating effective protection against the virus.
• FIG. 31 While passive transfer of vaccinated mouse serum yields lower protection than direct vaccination, transfer of serum from mice vaccinated with CoPoP yields (A) significantly reduced weight loss, (B) a higher rate of survival, and (C) lower clinical scores. This data supports the hypothesis that the immune response resulting from CoPoP vaccination is significantly antibody-mediated.
• FIG. 32 Shown in (A), his-tagged influenza antigens from various subtypes were obtained and tested for binding affinity with CoPoP. The binding potential of his-tagged antigens appears to be independent of subtype, with most antigens achieving approximately 100% binding with CoPoP after 3 hours of incubation at room temperature.
• Figure 33 Structures of some examples of synthetic adjuvants.
• DPPC:Cholesterol:CoPoP:MPLA where MPLA was each of these types of synthetic versions, and X varied was either 5,4,3,2,1. Results are shown for anti-Pfs25 titer for CP (PHAD), C3D6A (3D6A-PHAD), CP504 (PHAD-504), and CA (no MPLA).
• the present disclosure provides nanostructures comprising at least a monolayer.
• the structures can comprise a monolayer or a bilayer wherein the monolayer or bilayer comprise porphyrin-phospholipid conjugates that have cobalt chelated thereto such that the cobalt resides within the bilayer.
• the bilayer structures can form liposomes.
• the structures can comprise two monolayers (bilayers), where the hydrophobic groups of the two monolayers are opposed and the hydrophilic groups are exposed to the surface.
• bilayers are also applicable to monolayers.
• the bilayers or monolayers are sometimes referred to herein as“membranes”.
• cobalt porphyrins in the monolayer or bilayer can non- covalently bind polyhistidine-tagged molecules, such that at least part of the polyhistidine tag resides within the bilayer and the tagged molecule is presented on the surface of the bilayer.
• one or more histidine residues in the polyhistidine tag are coordinated to the cobalt metal core within the bilayer, thereby providing stability to the structure.
• the histidine residues of a polyhistidine tag may be coordinated to the cobalt metal in the core of the porphyrin in the membrane.
• the entire histidine tag may reside within the bilayer.
• a porphyrin phospholipid conjugate which has cobalt metal conjugated thereto is referred to herein as CoPoP.
• Liposomes wherein the bilayer comprises CoPoP are referred to herein as CoPoP liposomes.
• the CoPoP liposomes can be functionalized with histidine tagged molecules.
• his-tagged molecules means molecules - such as, for example, peptides, polypeptides, or proteins - which have a histidine tail.
• a peptide with a histidine tail is a his-tagged molecule.
• His-tag containing CoPoP liposomes are referred to herein as his-tagged CoPoP liposomes or his-tagged CoPoP.
• the CoPoP monolayers or bilayers functionalized with his-tagged presentation molecules of the present disclosure provide a platform for presentation of various molecules of interest in the circulation or for delivery to desired locations or for generation of specific immune responses to those his-tagged molecules. These molecules are referred to herein as presentation molecules (PMs). Structures containing his-tagged CoPoP bilayers, which have PMs attached to the histidine tag exhibit desirable stability.
• the his-tagged molecules are non-covalently attached to (coordinated to) the CoPoP and can be prepared by an incubation process. Therefore, the process does not need removal of reactive moieties - such as maleimide and the like - or exogenous catalysts or non-natural amino acids that are used in other types of conjugation chemistries.
• the cobalt-porphyrin may be in a bilayer in self-assembling liposomes enclosing therewithin an aqueous compartment. Alternatively, it may be in a single layer or bilayer coating that coats other nanoparticles.
• Cobalt-porphyrin phospholipid behaves like a conventional lipid with respect to its amphipathic nature. Therefore, monolayers or bilayers comprising CoPoP can be used for coating of nanoparticles by methods that are known to those skilled in the art.
• the bilayer or monolayer of the present disclosure may be present on other nanoparticles, such as, for example, in the form of a coating.
• the bilayer or monolayer containing cobalt-porphyrin is present as a coating on gold or silica nanoparticles, or other nanoparticles with a hydrophilic surface.
• the coating may be in the form of monolayers.
• the monolayer or bilayer containing cobalt-porphyrin e.g., cobalt porphyrin-phospholipid
• the monolayers may form micelles surrounding one or more hydrophobic molecules.
• This disclosure provides a nanostructure comprising a monolayer or a bilayer, wherein the monolayer or bilayer comprises: i) optionally, phospholipids and ii) porphyrin which has cobalt coordinated thereto forming cobalt-porphyrin.
• the nanostructure also has one or more polyhistidine-tagged presentation molecule. At least a portion of the polyhistidine tag resides in the hydrophobic portion of the monolayer or the bilayer and one or more histidines of the polyhistidine tag are coordinated to the cobalt in the cobalt- porphyrin. At least a portion of the polyhistidine-tagged presentation molecule is exposed to the outside of the nanostructure.
• the nanostructure can be in the form of a liposome that encloses an aqueous compartment. However, the nanostructure may also coat a hydrophilic or hydrophobic material such as a gold or silica nanoparticle.
• the cobalt porphyrin may be conjugated to a phospholipid to form a cobalt porphyrin-phospholipid conjugate.
• the cobalt porphyrin can make up from 1 to 100 mol % of the monolayer or the bilayer, including 0.1 mol% values and ranges therebetween. For example, the cobalt porphyrin can make up from 1 to 20 mole %, or from 5 to 10 mol% of the monolayer or the bilayer.
• the cobalt porphyrin makes up 100% of the monolayer or the bilayer, then there are no phospholipids present that are not conjugated to cobalt porphyrin.
• the bilayer or the monolayer can also comprise sterol and/or polyethylene glycol.
• the sterol can be cholesterol.
• the number of histidines in the polyhistidine-tag in the monolayer or bilayer can be from 2 to 20.
• the number of histidines in the polyhistidine-tag can be from 6 to 10.
• the number of histidines can be 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,
• the liposomes may be spherical or non- spherical.
• the size of the liposomes can be from 50 to 1000 nm or more.
• the liposomes have a size (e.g., a longest dimension such as, for example, a diameter) of 50 to 1000 nm, including all integer nm values and ranges therebetween.
• the size may be from 50 to 200 nm or from 20 to 1000 nm. If the liposomes are not spherical, the longest dimension can be from 50 to 1000 nm. These dimensions can be achieved while preserving the nanostructure width of the monolayer of the bilayer.
• the liposomes can carry cargo in the aqueous compartment.
• the cargo, or part thereof, can also, or alternatively, be incorporated in the monolayer or the bilayer.
• this disclosure provides a liposome comprising: a monolayer or a bilayer, wherein the monolayer or bilayer comprises cobalt-porphyrin phospholipid conjugate, optionally phospholipids that are not conjugated to cobalt porphyrin, and a polyhistidine-tagged presentation molecule, wherein at least a portion of the
• polyhistidine tag resides in the hydrophobic portion of the monolayer or the bilayer and one or more histidines of the polyhistidine tag are coordinated to the cobalt in the cobalt- porphyrin phospholipid conjugates. At least a portion of the polyhistidine-tagged presentation molecule is exposed to the outside of the nanostructure.
• the nanostructure such as a liposome, can enclose an aqueous compartment.
• the monolayer or the bilayer need not contain any phospholipids that are not conjugated to cobalt porphyrin and in this case only has cobalt porphyrin phospholipid conjugates.
• Cargo can be present in the aqueous compartment. The cargo need not reside exclusive in the aqueous compartment and a part thereof can reside in the monolayer or the bilayer.
• the disclosure also provides a monolayer or a bilayer, wherein the monolayer or bilayer comprises phospholipid monomers and porphyrin having cobalt coordinated thereto (forming cobalt-porphyrin).
• the monolayer or the bilayer has associated therewith one or more polyhistidine-tagged presentation molecules, wherein at least a portion of the polyhistidine tag resides in the hydrophobic portion of the monolayer or the bilayer.
• One or more histidines of the polyhistidine tag are coordinated to the cobalt in the cobalt-porphyrin and at least a portion of the polyhistidine-tagged presentation molecule is outside of the bilayer or the monolayer.
• the monolayer or the bilayer encloses an aqueous compartment or forms a coating on a nanoparticle - such as a gold or silica nanoparticle.
• the disclosure provides a nanostructure comprising a core, and a monolayer or a bilayer coating on the core, wherein the monolayer or bilayer comprises phospholipids, and porphyrin having cobalt coordinated thereto forming cobalt-porphyrin.
• the nanostructure can have one or more polyhistidine-tagged presentation molecules, wherein at least a portion of the polyhistidine tag resides in the hydrophobic portion of the monolayer or the bilayer and one or more histidines of the polyhistidine tag are coordinated to the cobalt in the cobalt- porphyrin. At least a portion of the polyhistidine-tagged presentation molecule is exposed to the outside of the nanoparticle.
• the core of the nanostructure can be a nanoparticle such as a gold or silica nanoparticle.
• the liposomes, or nanoparticles having a coating or monolayer or bilayer, as described herein can have presentation molecules thereon, which can be antigenic molecules and/or targeting molecules.
• presentation molecules can also provide targeting ability and/or imaging or other functionalities.
• Liposomes or other nanostructures comprising his-tagged polypeptides and
• CoPoP compositions exhibit high serum-stability with respect to binding of the his-tagged polypeptide to the liposome.
• serum such as diluted serum
• more than 60% of the his-tagged peptide remains bound to the CoPoP-containing bilayer after 24 hours incubation.
• more than 85% of the his-tagged peptide remains bound to the CoPoP layer after incubation with serum for 24 hours.
• the CoPoP liposomes or the his-tagged CoPoP liposomes can be loaded with cargo - which typically resides in the aqueous compartment, but may reside entirely or partially embedded in the bilayer - if it is hydrophobic or has a hydrophobic component.
• these structures can be used to load cargo in the aqueous compartment within the structures, or in the bilayer.
• the release of cargo from the CoPoP -liposomes can be triggered by near infrared (NIR) light.
• NIR near infrared
• the cargo can be released at desired locations - such as by being internalized in targeted cells or by light triggered release.
• the cobalt-porphyrin of the monolayers or bilayers is a porphyrin having a cobalt (Co) cation conjugated to the porphyrin.
• the porphyrin can be conjugated to a phospholipid (referred to herein as a cobalt porphyrin-phospholipid or cobalt porphyrin- phospholipid conjugate).
• porphyrin portion of the cobalt-porphyrin or cobalt-porphyrin conjugate making at least part of some of the bilayer of the liposomes or other structures comprise porphyrins, porphyrin derivatives, porphyrin analogs, or combinations thereof.
• exemplary porphyrins include hematoporphyrin, protoporphyrin, and tetraphenylporphyrin.
• Exemplary porphyrin derivatives include pyropheophorbides, bacteriochlorophylls, Chlorophyll A, benzoporphyrin derivatives, tetrahydroxyphenyl chlorins, purpurins, benzochlorins, naphthochlorins, verdins, rhodins, keto chlorins, azachlorins, bacteriochlorins, tolyporphyrins, and benzobacteriochlorins.
• porphyrin analogs include expanded porphyrin family members (such as texaphyrins, sapphyrins and hexaphyrins) and porphyrin isomers (such as porphycenes, inverted porphyrins, phthalocyanines, and naphthalocyanines).
• the cobalt-porphyrin can be a vitamin B12 (cobalamin) or derivative.
• the PoP is pyropheophorbide-phospholipid.
• the structure of pyropheophorbide-phospholipid is shown below:
• the layer has only C0P0P which has his-tagged presentation molecules embedded therein.
• the only phospholipid in the layer is C0P0P (i.e., C0P0P is 100 mol %).
• the layer (monolayer or bilayer) has only C0P0P and porphyrin conjugated phospholipids (PoP), wherein C0P0P has histidines embedded therein, with the histidines having a peptide or other presentation molecules attached thereto.
• the bilayer or monolayer in addition to the C0P0P, also has phospholipids which are not conjugated to porphyrin and therefore, not coordinated with Co. Such phospholipids may be referred to herein as“additional phospholipids”.
• the bilayer or monolayer may also comprise sterol and PEG-lipid.
• the bilayer or monolayer consists essentially of, or consists of C0P0P, phospholipids that are not conjugated to porphyrins, and optionally sterol and/or PEG, wherein the PEG may be conjugated to lipid.
• the only metal-PoP in the bilayer is C0P0P, which has his-tagged presentation molecules embedded therein.
• the only metal in the bilayer is Co.
• the bilayer of the liposomes comprises CoPoP and PoP.
• the bilayer can have additional phospholipids.
• the bilayer or monolayer may further comprise sterol and/or PEG.
• the PEG may be conjugated to lipid.
• the bilayer consists essentially of, or consists of CoPoP, PoP, additional phospholipids, and optionally sterol and/or PEG, wherein the PEG may be conjugated to lipid.
• the only metal-PoP in the bilayer is CoPoP. In one embodiment, the only metal in the bilayer is Co.
• the CoPoP is present in the nanoparticles from 0.1 to 10 mol % with the remainder 99.9 to 90 mol % being made up by additional lipids, with the percent being of the entire bilayer lipids.
• the combination of CoPoP can be present from 0.1 to 10 mol %
• sterol can be present from 0.1 to 50 mol %
• attenuated lipid A derivatives such as monophosphoryl lipid A or 3-deacylated
• monophosphoryl lipid A or a related analog can be present from 0 to 20 mol % or 0.1 to 20 mol %, and the remainder can be made up by additional phospholipids.
• the phospholipids are DOPC, DSPC, DMPC or combinations thereof, and sterol, if present, can be cholesterol.
• the combination of CoPoP and PoP may be present in the nanoparticles from 0.1 to 10 mol % with the remaining 99.9 to 90 mol% being made up by additional phospholipids.
• the combination of CoPoP and PoP can be present from 0.1 to 10 mol %
• sterol can be present from 0 to 50 mol % or 0.1 to 50 mol%
• PEG can be present from 0 to 20 mol % or 0.1 to 20 mol%
• the remainder can be made up by phospholipids.
• the phospholipids can be DOPC, DSPC, DMPC or combinations thereof and sterol, if present, can be cholesterol.
• phospholipid is a lipid having a hydrophilic head group having a phosphate group connected via a glycerol backbone to a hydrophobic lipid tail.
• the phospholipid comprises an acyl side chain of 6 to 22 carbons, including all integer number of carbons and ranges therebetween.
• the phospholipid in the porphyrin conjugate is l-palmitoyl-2-hydroxy-sn-glycero-3-phosphocholine.
• the phospholipid of the porphyrin conjugate may comprise, or consist essentially of phosphatidylcholine,
• phosphatidylethanoloamine phosphatidylserine and/or phosphatidylinositol.
• the porphyrin is conjugated to the glycerol group on the phospholipid by a carbon chain linker of 1 to 20 carbons, including all integer number of carbons therebetween.
• the bilayer of the liposomes also comprises other phospholipids.
• the fatty acid chains of these phospholipids may contain a suitable number of carbon atoms to form a bilayer.
• the fatty acid chain may contain 12, 14, 16, 18 or 20 carbon atoms.
• the bilayer comprises phosphatidylcholine, phosphatidylethanoloamine, phosphatidyl serine and/or phosphatidylinositol.
• the present bilayers and monolayers may also comprise sterols.
• the sterols may be animal sterols or plant sterols. Examples of sterols include cholesterol, sitosterol, stigmasterol, and cholesterol.
• cholesterol may be from 0 mol % to 50 mol %, or 0.1 to 50 mol %. In other embodiments, cholesterol may be present from 1 to 50 mol%, 5 to 45 mol%, 10 to 30 mol%.
• the bilayer or monolayer further comprises PEG- lipid.
• the PEG-lipid can be DSPE-PEG such as DSPE-PEG-2000, DSPE-PEG-5000 or other sizes of DSPE-PEG.
• the PEG-lipid is present in an amount of 0 to 20 mol % including all percentage amounts therebetween to the tenth decimal point.
• the average molecular weight of the PEG moiety can be between 500 and 5000 Daltons and all integer values and ranges therebetween.
• the bilayer or monolayer further comprises an adjuvant such as attenuated lipid A derivatives such as monophosphoryl lipid A or 3- deacylated monophosphoryl lipid A.
• an adjuvant such as attenuated lipid A derivatives such as monophosphoryl lipid A or 3- deacylated monophosphoryl lipid A.
• the histidine tag may carry a variety of presentation molecules of interest for various applications. At least one or both ends of the his-tag can reside close to the outer surface of the liposome. In one embodiment, at least one end of the polyhistidine tag is covalently attached to a presentation molecule. In one embodiment, the his-tag is a string of at least 2 histidines. In one embodiment, the his-tag is a string of 2-20 histidines. In one embodiment, the his-tag is a string of from 4-12 histidines and all integer numbers therebetween. In one embodiment, it is from 6-10 histidines. In one embodiment, it is 6, 7, 8, 9 or 10 histidines. In one embodiment, one end of the his-tag is free and a peptide or other molecule is attached to the other end. It is considered that at least a part of the his-tag is located within the bilayer such that it is coordinated to the cobalt metal core.
• the liposomes of the present disclosure can be substantially spherical and have a size (e.g., a longest dimension such as, for example, a diameter) of 30 nm to 250 nm, including all integers to the nm and ranges therebetween.
• the size of the liposomes is from 100-175 nm.
• at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99%, or 100% of the liposomes in the composition have a size of from 30 to 250 nm or from 100 to 175 nm.
• the liposomes or nanostructures can be more than 200 nm.
• the nanostructures are more than 1000 nm.
• the nanostructures are from 200 to 1000 nm.
• nanostructures may be spherical or non- spherical.
• the largest dimensions of the nanostructure are less than 200 nm, while preserving the nanostructure width of the monolayer or bilayer.
• the size of the nanostructure exceed 200 nm in some dimensions, while preserving the nanostructure width of the monolayer or bilayer.
• the size of the nanostructure exceed 1000 nm in some dimensions, while preserving the nanostructure width of the monolayer or bilayer.
• the disclosure provides a composition comprising liposomes or other structures of the present disclosure or a mixture of different liposomes or other structures.
• the compositions can also comprise a sterile, suitable carrier for administration to individuals including humans, such as, for example, a physiological buffer such as sucrose, dextrose, saline, pH buffering (such as from pH 5 to 9, from pH 7 to 8, from pH 7.2 to 7.6, (e.g., 7.4)) element such as histidine, citrate, or phosphate.
• the composition comprises at least 0.1% (w/v) CoPoP liposomes or his-tagged-CoPoP liposomes or other structures.
• the composition comprises from 0.1 to 100 mol% CoPoP liposomes or his-tagged CoPoP liposomes or other structures such as bilayer coated nanoparticles. In one embodiment, the composition comprises from 0.1 to 99 mol% CoPoP liposomes having his-tagged presentation molecules associated therewith.
• compositions of the present disclosure are free of maleimide or succinimidyl ester reactive groups.
• the tagged molecule to be attached to the membrane does not have a non-natural amino acid.
• the presentation molecule bearing the his-tag may be a small molecule or a macromolecule.
• the molecule is a peptide or a peptide derivative.
• the molecule is a polypeptide, polynucleotide, carbohydrate or polymer.
• the his-tag may be chemically conjugated to the molecule of interest.
• the his-tag may be incorporated into the primary amino acid sequence of a polypeptide.
• the molecule is an antigen, such as a peptide (2-50 amino acids and all peptides of amino acid lengths between 2 and 50) or a polypeptide (50 -1,000 amino acids and all polypeptides of amino acid lengths between 50 -1,000) or a protein (larger than 1,000 amino acids).
• the peptide, polypeptide or protein can have only naturally occurring amino acids, or can be a mixture of naturally occurring and non-naturally occurring amino acids, or can have only non-naturally occurring amino acids.
• the presentation molecules attached to the his-tag may be antigenic molecules, targeting molecules, therapeutic molecules, diagnostic molecules or molecules providing any other type of functionality.
• the tagged molecules may be used for targeting i.e., to guide the structures bearing the monolayers or bilayers to its targeted locations.
• a peptide ligand can be attached to the his-tag such that the ligand guides liposomes (or other structures) to cells that have receptors or recognition molecules for the ligands.
• the attached peptide could provide alternative or additional functionality - such as, for example, the attached peptide could provide therapeutic, diagnostic, or immunogenic functionality.
• the presentation molecule may be a targeting molecule such as an antibody, peptide, aptamer or other molecules such as folic acid.
• targeting molecule is used to refer to any molecule that can direct the bilayer bearing structure such as liposome, to a particular target, for example, by binding to a receptor or other molecule on the surface of a targeted cell.
• Targeting molecules may be proteins, peptides, nucleic acid molecules, saccharides or polysaccharides, receptor ligands or other small molecules.
• the degree of specificity can be modulated through the selection of the targeting molecule.
• antibodies typically exhibit high specificity. These can be polyclonal, monoclonal, fragments, recombinant, single chain, or nanobodies, many of which are commercially available or readily obtained using standard techniques.
• the presentation molecule can be an antigenic molecule - i.e., a molecule bearing antigenic epitopes.
• the molecule is a peptide.
• the peptide is a RGD bearing peptide sequence. Such sequences may be 7-20 amino acids or longer bearing an epitope.
• the peptide may be a fragment of, or may comprise an epitope of a polypeptide or protein that is part of a microorganism, such as a pathogenic microorganism (e.g., virus, bacteria, parasites, or fungi). Examples include respiratory syncytial virus, Borrelia burgdorferi (referred to herein as Lyme borreliae), influenza viruses, and the like.
• the peptide may be a fragment of a popypeptide or protein that is generally not immunogenic, such as, for example, a viral protein that is not known to be practically immunogenic.
• the peptide may be fragment of, or may comprise an epitope of, a HIV antigen, such as an HIV outer envelope protein.
• a HIV antigen such as an HIV outer envelope protein.
• the HIV antigen is gp41.
• the peptide can be membrane proximal external -region (MPER) of the gp41 envelope.
• MPER membrane proximal external -region
• Additional examples of antigens include, but are not limited to, DS-Cavl for RSV, OspA for Lyme disease, and hemagglutinin and neuraminidase for influenza.
• the present disclosure provides antigenic compositions.
• compositions comprise bilayer bearing structures in which an antigen having a histidine tail is non-covalently conjugated to the cobalt porphyrin (or cobalt porphyrin phospholipid) such that the his-tag is embedded in the bilayer and one or more epitopes of the antigen are exposed on the surface.
• the compositions may comprise adjuvants and other carriers known in the art. Examples of adjuvants include complete Freund's adjuvant, incomplete Freund's adjuvant, monophosphoryl lipid A (MPL), aluminum phosphate, aluminum hydroxide, alum, phosphorylated hexaacyl disaccharide (PFLAD), Sigma adjuvant sytem (SAS), AddaVax (Invitrogen), or saponin. Other carriers like wetting agents, emulsifiers, fillers etc. may also be used.
• a wide variety of cargo may be loaded into the liposomes or other structures of the present disclosure.
• the cargo can be delivered to desired locations using near infrared light.
• bioactive or therapeutic agents, pharmaceutical substances, or drugs can be encapsulated within the interior of the CoPoP liposome.
• the liposome comprises an active agent encapsulated therein, such as a therapeutic agent and/or a diagnostic agent, which can be a chemotherapy agent such as doxorubicin.
• chemotherapeutic agent doxorubicin could be actively loaded and released with NIR irradiation providing for robust and direct light-triggered release using CoPoP liposomes.
• the ratio of lipid to drug (or any other cargo agent) is from
• the ratio of lipid to drug/cargo ratio is 10: 1, 9: 1, 8: 1,
• the lipid used for calculating the ratios includes all the lipid including phospholipid that is part of the porphyrin phospholipid conjugate, additional phospholipids, or sterol, and lipid conjugated to PEG, if present.
• cargo is described as a drug in the disclosure, the description is equally applicable to any agent contained for treatment and/or delivery to a desired location, and the term“drug” is intended to refer to any agent.
• the agent may be contained, in whole or in part, within on in the PoP-liposomes- whether present in the aqueous compartment, the bilayer or both.
• the cargo loaded within the liposome or other carriers is a therapeutic agent.
• therapeutic agent is art-recognized and refers to any chemical moiety that is a biologically, physiologically, or pharmacologically active substance.
• therapeutic agents also referred to as “drugs” are described in well-known literature references such as the Merck Index, the Physicians Desk Reference, and The Pharmacological Basis of Therapeutics, and they include, without limitation, medicaments; vitamins; mineral supplements; substances used for the treatment, prevention, diagnosis, cure or mitigation of a disease or illness; substances which affect the structure or function of the body; or pro-drugs, which become biologically active or more active after they have been placed in a physiological environment.
• a therapeutic agent may be used which are capable of being released from the subject composition into adjacent tissues or fluids upon administration to a subject.
• Drugs that are known be loaded via active gradients include doxorubicin, daunorubicin, gemcitabine, epirubicin, topotecan, vincristine, mitoxantrone, ciprofloxacin and cisplatin.
• Therapeutic cargo also includes various antibiotics (such as gentamicin) or other agents effective against infections caused by bacteria, fungi, parasites, or other organisms. These drugs can be loaded and released in CoPoP liposomes.
• the cargo loaded in the liposome is a diagnostic agent.
• diagnostic agents include imaging agents, such as, for example, those containing radioisotopes such as indium or technetium; contrasting agents containing iodine or gadolinium; enzymes such as, for example, horse radish peroxidase, GFP, alkaline phosphatase, or beta.-galactosidase; fluorescent substances such as, for example, europium derivatives; luminescent substances such as, for example, N-methylacrydium derivatives or the like.
• the cargo may comprise more than one agent.
• cargo may comprise a combinations of diagnostic, therapeutic, immunogenic, and/or imaging agents, and/or any other type of agents.
• the same agent can have multiple functionalities.
• an agent can be diagnostic and therapeutic, or an agent can be imaging and immunogenic and the like.
• the structures formed by the layers of the present disclosure are serum stable.
• the his-tag binding stability to the CoPoP bilayers is stable when incubated in 50% bovine serum at room temperature for 24 hours.
• these structures can be stable under serum or concentrated or diluted serum conditions.
• the present disclosure also provides methods for using structures bearing the bilayers as described herein.
• this disclosure provides a method of eliciting an immune response in a host.
• the immune response may generate antibodies.
• the method comprises administering to an individual a composition comprising a structure bearing Co PoP bilayers to which is conjugated a histidine tagged antigen.
• the compositions may be administered by any standard route of immunication including subcutaneous, intradermal, intramuscular, intratumoral, or any other route.
• the compositions may be administered in a single administration or may be administered in multiple administrations including booster shots.
• Antibody titres can be measured to monitor the immune response.
• the present nanostructures can be used for reducing antibody titer against desired antigens. For example, if immunogenicity is desired to be reduced, nanostructures in which PS (or other) containing phospholipids are present can be used. Compositions comprising these nanostructures can be administered for reducing immunogenicity.
• the disclosure provides a method of delivery of agents contained as cargo in the liposomes or other nanostructures to desired locations.
• the agent may be contained, in whole or in part, within or in the CoPoP liposomes - whether present in the aqueous compartment, the bilayer or both.
• the method comprises 1) providing a
• composition comprising liposomes or other structures bearing the bilayers of the present disclosure optionally comprising cargo (such as an active agent); 2) allowing the liposomes to reach a selected or desired destination; 3) irradiating the liposome with radiation having a wavelength of near-infrared under conditions such that at least a portion of the cargo is released from the liposome.
• cargo such as an active agent
• the cargo can alternatively, or additionally reach the interior of the cell by the liposomes being internalized and then releasing the cargo upon action of intracellular processes.
• the liposomes may be irradiated with near-infrared light from a laser of power
• the liposomes may be irradiated for up to 30 minutes or less. In various embodiments, the liposomes in vitro or in vivo may be irradiated from 0.5 to 30 minutes and all values to the tenth decimal place therebetween. In one embodiment, the liposomes are irradiated with a 658 nm laser diode for up to 10 minutes.
• the liposomes are irradiated with wavelengths of 665 or 671 nm.
• the infrared radiation can be delivered to the desired area directly by shining laser light on the area or fiber optic probes may be used.
• the fiber optic probe can be inserted into the tumor (i.e., via a catheter or endoscopic device) to provide irradiation to a localized area.
• the disclosure provides a method of preparing bilayers comprising CoPoPs.
• Freebase PoP can be produced by esterifying a monocarboxlic acid porphyrin such as pyropheophorbide-a with 2-palmitoyl-2-hydroxy-sn-glycero-3- phosphocholine (lyso-C16-PC), Avanti #855675P) using l-Ethyl-3-(3- dimethylaminopropyl)carbodiimide and 4-dimethylaminopyridine in chloroform at a 1 : 1 :2:2 lyso-C16-PC:Pyro:EDC:DMAP molar ratio by stirring overnight at room temperature. The PoP is then purified by silica gel chromatography.
• a monocarboxlic acid porphyrin such as pyropheophorbide-a with 2-palmitoyl-2-hydroxy-sn-glycero-3- phosphocholine (lyso-C16-PC), Avanti #855675P) using l-Ethyl-3-(
• CoPoP can be generated by contacting porphyrin-phospholipid conjugate with a molar excess (e.g., 10-fold molar excess) of a cobalt salt (e.g., cobalt (II) acetate tetrahydrate) in a solvent (e.g., methanol) in the dark.
• a cobalt salt e.g., cobalt (II) acetate tetrahydrate
• solvent e.g., methanol
• this disclosure provides a method for coating a nanoparticle with a cobalt-porphyrin (e.g., CoPoP) bilayer or monolayer.
• the method generally comprises hydrating nanoparticles with a lipid solution in order to disperse the particles in water.
• the composition comprising the liposomes in a suitable carrier can be administered to individuals by any suitable route.
• it is administered by intravenous infusion such that it will enter the vasculature (circulatory system).
• the composition may be administered systemically or may be administered directly into the blood supply for a particular organ or tissue or tumor.
• NIR When irradiated by NIR, the contents of the PoP liposomes may be released within the circulatory system and may then enter the surrounding tissue.
• compositions, and methods of the present disclosure are described:
• a nanostructure e.g., a liposome
• a monolayer or bilayer wherein the monolayer or bilayer comprises: i) optionally, phospholipid, and ii) porphyrin having cobalt coordinated thereto forming cobalt-porphyrin; and b) optionally, a polyhistidine-tagged presentation molecule, where at least a portion of the polyhistidine tag resides in the hydrophobic portion of the monolayer or the bilayer or monolayer and one or more histidines of the polyhistidine tag are coordinated to the cobalt in the cobalt-porphyrin, where at least a portion of the polyhistidine-tagged presentation molecule is exposed to the outside of the nanostructure (e.g., liposome), and where, in the case of liposomes, the liposome encloses an aqueous compartment.
• the nanostructure e.g., liposome
• a nanostructure (e.g., liposome) of Statement 1 where the cobalt porphyrin is conjugated to a phospholipid to form a cobalt porphyrin-phospholipid conjugate.
• a nanostructure (e.g., liposome) of Statement 2 where the cobalt porphyrin-phospholipid conjugate makes up from 1 to 25 mol % of the monolayer or the bilayer.
• a nanostructure e.g., liposome of any one of Statements 1 to 4, where the bilayer further comprises a sterol (e.g., cholesterol).
• a sterol e.g., cholesterol
• a nanostructure e.g., liposome of any one of Statements 1 to 4, where the bilayer further comprises phosphatidylserine and, optionally, cholesterol.
• a nanostructure e.g., liposome of any one of Statements 1 to 4, where the polyhistidine- tag comprises 6 to 10 histidine residues.
• a nanostructure e.g., liposome of any one of Statements 1 to 4, where size of the liposome is 50 nm to 200 nm.
• a nanostructure e.g., liposome of any one of Statements 1 to 4, where the nanostructure (e.g., liposome) comprises a cargo and, in the case of liposomes, at least a portion of the cargo resides in the aqueous compartment of the liposome.
• a nanostructure e.g., liposome of any one of the preceding Statements, where the presentation molecule is a peptide of from 4 to 50 amino acids, said number of amino acids not including the histidines of the his-tag.
• a nanostructure e.g., liposome of any one of the preceding Statements, wherein the presentation molecule is a protein from 4 to 500 kDa.
• a nanostructure e.g., liposome of any one of the preceding Statements, where the presentation molecule is an antigenic molecule and the monolayer or the bilayer further comprises an adjuvant incorporated therein.
• a nanostructure comprising: a) a core; and b) a monolayer or a bilayer on said core, wherein the monolayer or bilayer comprises: i) optionally, phospholipid monomers, and ii) porphyrin having cobalt coordinated thereto forming cobalt-porphyrin (e.g., CoPoP); and c) optionally, a polyhistidine-tagged presentation molecule, where at least a portion of the polyhistidine tag resides in the hydrophobic portion of the monolayer or the bilayer, one or more histidines of the polyhistidine tag are coordinated to the cobalt in the cobalt-porphyrin, and at least a portion of the polyhistidine-tagged presentation molecule is exposed on the outside of the nanostructure.
• cobalt-porphyrin e.g., CoPoP
• a method of targeted delivery of a cargo comprising: a) administering to an individual a composition comprising nanostructures (e.g., liposomes) of any one of Statements 9 to 16 or a combination of nanostructures (e.g., liposomes) of any one of Statements 9 to 16 in a pharmaceutical carrier; and b) after a suitable period of time to allow the nanostructures (e.g., liposomes) to reach a desired location in the individual, exposing the liposomes to near infrared radiation of a wavelength from 650 to 1000 nm to effect release of the cargo from the liposomes.
• nanostructures e.g., liposomes
• a method for generating an immune response in a host individual comprising
• compositions comprising nanostructures (e.g., liposomes) of any one of Statements 1 to 16 or a combination nanostructures (e.g., liposomes) of any one of Statements 1 to 16 of in a pharmaceutical carrier, where the presentation molecule comprises an immunogenic epitope.
• nanostructures e.g., liposomes
• a combination nanostructures e.g., liposomes
• This example describes the synthesis and functionalization of cobalt porphyrin-phospholipid (CoPoP) bilayers with histidine-tagged ligands and antigens.
• CoPoP cobalt porphyrin-phospholipid
• the recombinant heptahistidine-tagged cerulean-venus fusion reporter protein was produced in Escherichia coli and was purified and characterized as previously described. Stoichiometry approximations were based on the assumption that each -100 nm liposome contains 80,000 lipids.
• PoP-lipid, PoP-liposomes and PoP-gold Freebase (2H) PoP sn-l-palmitoyl sn-2-pyropheophorbide phosphtatidylcholine was synthesized as previously described. CoPoP was generated by stirring 100 mg 2H-PoP with 10 fold molar excess of cobalt (II) acetate tetrahydrate in 4 mL methanol for 17 hours in the dark. Reaction completion and product purity was monitored by TLC (>90% purity). The solvent was then removed by rotary evaporation and PoP was extracted with chi oroform:methanol: water (1 : 1.8: 1) 3 times.
• Ni-PoP Ni (II) acetate tetrahdrate was used and incubated for 17 hours.
• Zn-PoP Zn (II) acetate dehydrate was used and incubated for 17 hours.
• Mn-PoP Mn (II) acetate was used and incubated for 30 hours.
• Cu-PoP Cu (II) acetate was used and incubated in tetrahydrofuran for 3 hours.
• PoP -liposomes were formulated at a 1 mg scale. After dissolving lipids in chloroform in a test tube, the solvent was evaporated and the film was further dried under vacuum overnight. Lipids were rehydrated with 1 mL of phosphate buffered saline (PBS), sonicated, subjected to 10 freeze-thaw cycles and then extruded through 100 nm
• PBS phosphate buffered saline
• polycarbonate membranes VWR # 28157-790 with a handheld extruder (Avanti # 610000).
• liposomes were formed with 10 mol % PoP along with 85 mol % DOPC (Avanti # 850375P), and 5 mol % PEG-lipid (Avanti # 880120P).
• Ni- NTA liposomes included 10 molar % Ni-NTA lipid dioleoyl-glycero-Ni-NTA (Avanti # 790404P) as well as 10 molar % 2H-PoP.
• Liposomes incorporating free Co-porphyrin included 10 molar % Co-pyropheophorbide with 85 mol % DOPC and 5 mol % PEG-lipid.
• Co-NT A-liposome was prepared using liposomes containing 10 mol % dioleoyl-gycero-NTA (Avanti # 790528P). Liposomes were incubated with 20 mg/mL cobalt (II) chloride for 2 hours and then dialized in PBS. Sulforhodamine B loading liposomes contained 10 mol % PoP, 35 mol % cholesterol (Avanti # 700000P), 55 mol % DOPC and PEG-lipid as indicated.
• a solution of sulforhodamine B (VWR # 89139-502) was used to hydrate the lipid film, which was then freeze-thawed then sonicated. Unentrapped dye was removed with a 10 mL Sephadex G-75 (VWR # 95016-784) column followed by dialysis in PBS. For bilayer integrity and quantitative cell binding studies, 50 mM dye was used, whereas microscopy studies used 10 mM dye.
• U-87 and MCF-7 cell lines were obtained from ATCC and cultured according to vendor protocol. 2xl0 4 cells were seeded overnight in 96-well-plate wells. 500 ng RGD-His peptide was bound with 20 pg of sulforhodamine B loaded liposomes and liposomes were incubated with cells for 2 h. Media was removed, cells were washed with PBS 3 times and then cells and liposomes were lysed with a 1 % Triton X-100 solution. Liposomal uptake was assessed by measuring the fluorescence of sulforhodamine B.
• confocal imaging 10 4 cells were seeded overnight in a Nunc chamber slide (Nunc # 155411) in DMEM with 10% fetal bovine serum (FBS). 20 pg of liposomes were added to the serum containing media and incubated for 2h. Media was removed and the cells were washed with PBS 3 times. Fresh media was added and cells were imaged with microscopy using a Zeiss LSM 710 confocal fluorescence microscope. Gold imaging was carried out in the same way but 633 nm light was used for both excitation and emission for back scatter imaging. After peptide binding, gold was centrifuged to remove any unbound RGD peptide.
• FBS fetal bovine serum
• mice were inoculated on the flank with U87 cells and mice were treated when tumor growth reached 4-5 mm diameter.
• Mice were intravenously injected with 200 pL of sulforhodamine B-loaded liposomes (1 mg/mL llipid) targeted with or without cRGD-his. 45 minutes after injection mice were sacrificed, organs were extracted, weighed, mechanically homogenized in a 0.2 % Triton X-100 solution and fluorescence was assessed to determine biodistribution.
• DOPC Cholesterol :MPL:PoP at a molar ratio of 50:30:5:5.
• Freund’s adjuvant the peptide was mixed directly in Fruend’s complete adjuvant (Fisher # PI-77140) and injected. 4 weeks following the first injection, or as indicated, blood was collected from the submandibular vein and serum was obtained following blood clotting and centrifugation at 2000 ref for 15 min and stored at -80 °C.
• Anti-MPER titer was assessed by ELISA in 96-well streptavi din-coated plates
• Viral entry experiments were carried out as previously described.
• HIV-1 was produced by co-transfection of pHXB2-env and pNL4-3.HSA.R-E- in 293T cells. 2 days post-transfection, the cell media was passed through a 0.45 pm filter and centrifuged. The viral pellet was dried, re-suspended in 600 pL of PBS and stored at -80 °C. The infectious titer of HIV-1 stock was determined by X-Gal staining as previously described.
• Cell viability was then measured using a CellTiter-Fluor Assay (Promega) according to manufacturer protocol. Viral entry level was then measured by a luciferase assay system (ONE-Glo, Promega) according to manufacturer protocol and was normalized to the virus only sample. Data were further normalized to cellular viability (all groups exhibited viability within 10% of the control untreated cells).
• 2-pyropheophorbide phosphtatidylcholine chelates was generated with the transition metals Co, Cu, Zn, Ni and Mn (Fig. lc).
• PoP bilayers were then formed with 10 molar % metallo- PoP along with 85 molar % dioleoylphosphocholine (DOPC) and 5 molar % polyethylene glycol-conjugated distearoylphosphoethanolamine (PEG-lipid) via extrusion into 100 nm liposomes. His-tagged protein binding to PoP bilayers was assessed with a fluorescent protein reporter. As shown in Fig.
• the system comprised a fusion protein made up of two linked fluorescent proteins; Cerulean (blue emission) and Venus (green emission). Due to their linked proximity and spectral overlap, Cerulean serves as a Forster resonance energy transfer (FRET) donor for Venus, so that Cerulean excitation results in FRET emission from Venus. Cerulean was tagged at its C-terminus with a heptahistidine tag. However, if bound to a PoP bilayer, energy transfer from Cerulean is diverted to the bilayer itself, which is absorbing in the Cerulean emission range and thus competes with FRET to Venus. On the other hand, because Venus is not directly attached to the photonic bilayer, it is not completely quenched upon direct excitation, which enables tracking of the bound fusion protein.
• FRET Forster resonance energy transfer
• a 3-color electrophoretic mobility shift assay was developed to assess reporter fusion protein binding to various PoP liposomes.
• 2.5 pg protein was incubated with the 50 pg of various PoP liposomes for 24 hours and then subjected to agarose gel electrophoresis.
• Fig. 2b when the PoP -liposomes were imaged only the free base (2H) liposomes were readily visualized, along with the Zn-PoP liposomes to a lesser degree. This demonstrates that the metals have a quenching effect on the PoP and confirms they were stably chelated in the bilayer.
• the liposomes exhibited minimal electrophoretic mobility due to their relatively large size.
• the same gel was imaged using Cerulean excitation and Venus emission to probe for inhibition of FRET, which would be indicative of the fusion protein binding to PoP liposomes.
• All the samples exhibited the same amount of FRET and migrated the same distance as the free protein with the exception of the protein incubated with CoPoP liposomes, in which case FRET disappeared completely (middle image).
• Venus was directly excited and imaged. Only with the CoPoP liposomes was the reported protein co-localized with the liposomes. Together, these images demonstrate that the protein bound quantitatively to CoPoP liposomes. Solution-based studies confirmed this finding (Fig.
• Ni(II) and Cu(II) porphyrin chelates can coordinate completely with the 4 surrounding macrocyclic nitrogens atoms without axial ligands.
• the ligand binding strength is likely insufficient to confer stable polyhistidine binding.
• the FRET channel was unquenched, confirming a lack of binding to the Ni-NTA liposomes.
• the protein when incubated with the CoPoP liposomes, the protein stably bound with a complete disappearance of the FRET channel and decreased electrophoretic mobility that was consistent with the protein remaining bound to liposomes.
• Ni-NTA-lipid For biomedical applications, an intractable obstacle of using Ni-NTA-lipid is that it does not maintain stable His-tag binding in biological media such as serum.
• biological media such as serum.
• fetal bovine serum was added at a 1 : 1 volume ratio to a solution of liposomes that had bound the His- tagged protein.
• Ni-NTA liposomes did not fully sequester all the protein, which is consistent with the weak binding exhibited in the EMSA result.
• the histidine side chain comprises an imidazole group
• an imidazole competition assay was used to compare the Ni-NTA and CoPoP liposomes binding stability with His-tagged polypeptides.
• CoPoP liposomes maintained over 75% binding to the reporter protein even at concentration approaching 1 M imidazole. This represents an approximate 10 million fold imidazole excess over the 100 nM protein concentration used in the binding study.
• the Ni-NTA liposomes released over 90% the His-tag in the presence of just 30 mM imidazole.
• the drastically stronger binding of the CoPoP liposome to the His-tag may be attributed to at least 2 factors; the superior stable chelation of Co(III) to imidazole groups and the protected hydrophobic environment of the CoPoP bilayer which limits access to competing external molecules.
• CoPoP could bind a fluorescent peptide in solution ( Figure 7a). However, the binding of Co- NTA and Ni-NTA was not maintained during gel filtration chromatography ( Figure 7b). Liposomes formed with Co-NTA and Ni-NTA, but not CoPoP, released the peptide when incubated in serum ( Figure 7c). This demonstrates the significance of bilayer-confmed polyhistidine binding.
• Co-pyro simple liposome-inserted cobalt porphyrin
• Peptide targeting has attracted interest for use as disease and tissue-specific
• the short RGD tripeptide which is found in fibronectin and vibronectin, is a promising targeting ligand for its effective binding to the integrin anb3 expressed on tumor endothelial cells.
• CoPoP liposomes were examined to verify whether they can be delivered to molecular receptors on target cells via a His-tagged ligand approach with the short linear amino acid sequence GRGD SPKGAGAKG-HHHHHHH (SEQ ID NO: l).
• Carboxy fluorescein (FAM) was labeled on the N-terminus to enable detection of binding to PoP- liposome via FRET. It has been shown that linear RGD peptides can be labeled with fluorophores without disrupting integrin binding.
• lipid composition was varied to determine the effect of membrane fluidity on His-tag binding.
• Liposomes were formed with 90 mol % of either DSPC, DMPC or DOPC along 10 mol % CoPoP, Alternatively, 50 mol % cholesterol was incorporated in the bilayer with a corresponding reduction in the amount of standard lipid used.
• DSPC forms rigid, gel-phase bilayers at room temperature, whereas DMPC and DOPC have lower transition temperatures and are in the liquid crystal phase. Cholesterol occupies space in the bilayer and can have a moderating effect on membrane fluidity. Interestingly, no major differences were observed in the peptide binding rate to membranes of different
• RGD-decorated liposomes were assessed whether they could bind to their molecular targets with the established cell-line pair of U87 glioblastoma cells (RGD- binding) and MCF7 breast cancer cells (RGD non-binding).
• RGD-binding the established cell-line pair of U87 glioblastoma cells
• MCF7 breast cancer cells RGD non-binding
• liposomes were first incubated with the His-tagged RGD peptide and then with both cell lines. Approximately 550 peptides were attached to each liposome. Liposomal uptake was assessed by examining the fluorescence in the cells following washing and lysis (to remove any effects of cargo self-quenching). As shown in Fig.
• CoPoP liposomes can be loaded with cargo in the core of the liposome, be labeled with a His-tagged targeting peptide without inducing cargo leakage, and be directed to molecular receptors expressed on cells expressing specific surface proteins in vitro and in vivo.
• Liposomes represent only a subset of all the types of nanomaterials used in biomedical applications. CoPoP was assessed as a generalized surface coating with selective adhesion for His-tags. Gold nanoparticles were used as a model nanoparticle since these have are used in numerous biological applications. Using an established protocol to lipid-coat gold nanospheres, a citrate-stabilized 60 nm gold dispersion was used to hydrate a thin film of PoP -lipid. Upon repeated centrifugation and re-suspension, the citrate was displaced, causing the nanospheres to aggregate (Fig. 13a). However, in the presence of PoP-lipid, the nanospheres became coated and remained dispersible.
• PoP-coated nanospheres Compared to citrate-stabilized gold, PoP-coated nanospheres had a slightly larger hydrodynamic size, corresponding to a bilayer coating on the gold (Fig. 13b). The presence of the coating following His-tag binding did not influence the plasmonic peak of the gold at 540 nm, demonstrating the mild nature of the ligand binding (Fig. 13c). As shown in Figure 13d, only RGD-His CoPoP-coated gold nanoparticles targeted U87 cells and free RGD inhibited the binding as determined by backscatter microscopy. CoPoP gold alone, as well as 2H-PoP-coated gold with the RGD-His peptide were ineffective at targeting U87 cells.
• TLR-4 Toll-like receptor 4
• MPL monophosphoryl lipid A
• a liposomal-peptide vaccination system was used with the MPER-His sequence NEQELLELDKW ASL WN GGKGG-HHHHHHH (SEQ ID NO: 11).
• the MPER- His peptide was bound to CoPoP liposomes containing MPL.
• a single injection containing 25 pg MPER-His and 25 pg of MPL was administered to BALB/c mice and to athymic nude mice. This elicited a titer on the order of 10 4 in both BALB/c mice and nude mice, demonstrating a strong humoral immune response (Fig. 6a). This may be significant since HIV infects helper T cell populations, making B cell mediated responses important.
• the vaccination protocol resulted in both B cell and T cell- mediated immunity.
• a vaccine was developed that made use of his-tagged Pfs25, a recombinant protein derived from Plasmodium falciparum and liposomes containing CoPoP and MPL A.
• Liposome Preparation For generation of CoPoP and 2H-PoP liposomes, 1,2- dimyristoyl-sn-glycero-3-phosphocholine (DMPC), cholesterol (CHOL), monophosphoryl lipid A (MPLA) and CoPoP (or 2H-PoP) were dissolved in chloroform at the indicated molar ratio (Table 2). A dried lipid film was formed after N2 stream and vacuum overnight and was rehydrated in PBS to a final lipid concentration of 3 mg/mL. The liposomal suspension was subjected to 11 times freeze/thaw cycles using ice cold CCk/acetone and a water bath followed by extrusion 10 times at 60 °C through 200 nm polycarbonate membranes.
• DMPC 1,2- dimyristoyl-sn-glycero-3-phosphocholine
• MPLA monophosphoryl lipid A
• CoPoP or 2H-PoP
• Psf25 insect protein Recombinant subunit Pfs25 purified from super sf9 cells, concentration determined by BCA assay as 1 mg/mL
• Psf25 incubated in H2O served as a control.
• BSA was combined with liposomes as a negative control.
• the binding of Psf25 protein and liposomes was determined by a micro-centrifugal filtration method.
• Table 2 Formulation of Psf25 CoPoP/MPLA liposomes for each mouse injection
• CD-I mice 8 week females, Envigo received intramuscular injections (i.m.) of 5, 0.5 and 0.05 pg Psf25 protein. Where indicated, the injections also included 20 pg MPLA incorporated into the liposomes (Avanti No.
• ISA720 was also used as an adjuvant incubated with 5pg Psf25 protein.
• the treatment groups and flow chart are shown in Table 3.
• Serum anti-Psf25 IgG level by ELISA Anti-Psf25 titer was assessed by enzyme-linked immunosorbent assay (ELISA) in 96-well plates (Thermo, Maxisorp). Elis- tagged Psf25 (0.1 pg) in 100 pi coating buffer (3.03 g Na2CCh and 6.0 g NaHCCh/lL distilled water, pH 9.6) was incubated in the wells for overnight at 4 °C. Wells were washed with PBS containing 0.1 % Tween (PBS-T) for 3 times and block with PBS containing 0.1 % casein (PBS-C) and then incubated for 2 h.
• PBS-T PBS containing 0.1 % Tween
• PBS-C casein
• CD-I mice were vaccinated with the CoPoP/MPLA/Pfs25 liposomes conjugated with or without Psf25(with concentration of 5, 0.5 and 0.05 pg); via i.m. or with free Psf25 (with or without ISA70) on day 0 (prime) and day 21 (boost).
• serum was collected and anti-Psf25 IgG titers were determined by ELISA (Fig. 15A and Fig. 15B).
• Mice preboost with the CoPoP/MPLA/Psf25 liposomes showed similar IgG level in serum in both 5 pg and 0.5pg Psf25 conjugated groups.
• the IgG titer of CoPoP/MPLA/Pfs25 liposomes conjugated with 0.05 pg Psf25 protein switch from 1/1000 to 1/15000 after boosting, similar results were shown in G6, which represent the 5pg Psf25 protein incubated with ISA70.
• This data is also reflected in Fig. 16, which shows titers of 0.05 ug Pfs25 in CoPoP/MPLA liposomes producing a higher titer than 5 pg Pfs25 in ISA720.
• the peptides examined are shown in Fig. 17A.
• the average size of the CoPoP liposomes before and after different NANP binding was measured by dynamic light scattering was 122.9 and 139 nm,
• CoPoP liposomes containing phosphatidylserine was used to reduce antibody response to his-tagged presentation molecules. Liposomes were formed with 10:30:30:30 CoPoP:phosphatidylserine:DOPC:Cholesterol via thin film hydration and extrusion. His-tagged MPER was then bound to the liposomes. These PS liposomes were injected via footpad to mice 4 weeks and 2 weeks prior to vaccination with CoPoP/MPLA liposomes decorated with MPER. As shown in Fig. 18, pretreatment with PS liposomes resulted in decreased IgG titers against MPER.
• PS phosphatidylserine
• CoPoP liposomes were targeted to cells via his-tagged cell penetrating peptides.
• the following his-tagged cell penetrating peptides were obtained:
• HHHHHHHGRKKRRQRRRPPQ (SEQ ID NO: 13) (TAT peptide);
• HHHHHHHRRRRRRRR (SEQ ID NO: 14) (R8 peptide);
• CoPoP liposomes were used with a pre-fusion RSV antigen (a his-tagged antigen, DS-Cavl for RSV). His-tagged antigens can be used with the pre-fusion RSV antigen (a his-tagged antigen, DS-Cavl for RSV). His-tagged antigens can be used with the pre-fusion RSV antigen (a his-tagged antigen, DS-Cavl for RSV). His-tagged antigens can be used with the
• CoPoP/PHAD system for generating functional antibodies.
• the antigen DS-Cavl is a pre-fusion form of the F protein on the surface of the RSV virus. His-tagged DS-Cavl has been show to induce neutralizing antibodies to RSV A2.
• CoPoP liposomes bind his-tagged proteins with simple mixing of antigen and liposomes, so that the resulting liposomes become decorated with conformationally-intact antigens, presented in a uniform orientation.
• the antigen binding is non-covalent stable in biological environments. It was shown (with another his-tagged antigen, Pfs25, a malaria transmission blocking antigen) that CoPoP liposomes result in improved antigen delivery to antigen presenting cells in vitro and in vivo.
• a 50 pL volume of antigen-liposome solution is prepared using CoPoP and PoP (also referred to as 2H) and diluted to 200 pL. Reference samples of liposomes without antigen, and antigen without liposomes, were also prepared. Samples were centrifuged at 20,000 ref for 90 minutes, and the supernatant was extracted from the resulting liposome pellet. An equal volume of BCA was added, to a total volume of 400 pL. Samples were then incubated in a water bath at 60 °C for 10 minutes. A volume of 100 pL of each sample are transferred to each of 3 wells of a 96-well plate and the absorbance was measured at 562 nm. The absorbance difference between the antigen-liposome supernatant and liposome-only reference samples were used to calculate the percentage binding, with higher absorbance corresponding with a higher protein concentration in the supernatant and thus a lower binding.
• CoPoP and PoP also referred to as 2H
• mice were then injected with RSV antigen in conjunction with one of six adjuvants: CoPoP with PHAD, CoPoP without PHAD, 2HPoP with PHAD, aluminum hydroxide (Alum), Sigma Adjuvant System (SAS), and AddaVax.
• CoPoP with PHAD CoPoP with PHAD
• CoPoP without PHAD CoPoP without PHAD
• 2HPoP with PHAD aluminum hydroxide
• SAS Sigma Adjuvant System
• AddaVax additives
• mice from the remaining five groups exhibited detectable IgG titers.
• IgG titers of mice vaccinated with CoPoP, 2HPoP, and SAS all showed significant increase; however, CoPoP with PHAD remained the most effective formulation for inducing antibody production (Fig 2 IB).
• the mean antibody titer for the CoPoP/PHAD group exceeded the other five groups, and the CoPoP/PHAD was the only group without mice that were unresponsive to the vaccine after the booster injection.
• CoPoP liposomes were used with OspA, a Lyme disease antigen. His-tagged antigens can be used with the CoPoP/PHAD system for generating functional antibodies.
• OspA is a lyme disease antigen.
• a his-tagged OspA based on the B31 strain protein sequence without the lipid tail was generated, and purified it as shown in Figure 22.
• proteoliposomes with human at 37 °C did not significantly increase the fluorescence signal after 12 days. This basically indicates that OspA remains mainly associated to the
• CoPoP liposome exhibited more than a hundred-fold increase in stability compared to nickel-chelating liposomes due to the strategic spatial location of the metallochelating bond within the hydrophobic bilayer. Serum- stable antigen binding ensures integrity of the proteoliposomes during transit to draining lymph nodes.
• nanoparticle scaffold This highlights the importance of proper antigenic epitope presentation on the particle surface.
• polyhistidine tag was appended at the N-terminus opposite to the locality of protective epitopes to ensure epitope accessibility on the liposomal surface and avoid possible occlusion of the important C-terminal epitopes. This configuration basically mimics the lipoprotein integration to the outer membrane of Lyme borreliae.
• the macrophage selective uptake of PoP/PHAD liposomes in the mixed form further implicates that physical association of antigen to liposomes may be necessary for liposomal adjuvanticity.
• Co-delivery of surface-exposed antigen and immunostimulant to immune cells is an important facet of the CoPoP/PHAD liposome.
• B. hermsii which lacks the ospa gene, has no apparent band. Minimal non-specific bands were observed for E. coli lysate with histidine-tagged OspA. Lower molecular weight observed for the OspA band is due to the substitution of the lipidation signal sequence with a shorter polyhistidine segment.
• CoPoP liposomes were used with hemagglutinin antigens and neuraminidase for influenza. His-tagged antigens can be used with the CoPoP/PHAD system for generating functional antibodies.
• Influenza hemagglutinin is the major surface antigen on the flu virus and a major vaccine target.
• H3 strain HA was obtained.
• his-tagged HA bound effectively to CoPoP liposomes.
• a 50 pL volume of antigen-liposome solution is prepared using CoPoP and
• HAs As shown in Figure 32A, various HA and NA proteins bound to CoPoP liposomes. When immunized, all the HAs could generate specific antibodies with minimal cross reactivity (Figure 32B).
• His-tagged Pfs25 was mixed in a 1 :4 mass ratio of antigemCoPoP and mice were immunized on day 0 and day 21. Serum was collected on day 42 and serum was assessed for Pfs25 binding IgG ELISA.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Virology (AREA)
• Immunology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Molecular Biology (AREA)
• Gastroenterology & Hepatology (AREA)
• Tropical Medicine & Parasitology (AREA)
• Mycology (AREA)
• Microbiology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Communicable Diseases (AREA)
• General Chemical & Material Sciences (AREA)
• Oncology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• AIDS & HIV (AREA)
• Zoology (AREA)
• Biophysics (AREA)
• Dispersion Chemistry (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Priority Applications (5)

Applications Claiming Priority (2)

Publications (1)

Family

ID=73028666

Family Applications (1)

Country Status (6)

Cited By (1)

Citations (2)

Family Cites Families (1)

• 2020
  • 2020-04-29 WO PCT/US2020/030537 patent/WO2020223395A1/en unknown
  • 2020-04-29 CN CN202080048088.8A patent/CN114502159A/zh active Pending
  • 2020-04-29 JP JP2021564509A patent/JP2022530539A/ja active Pending
  • 2020-04-29 AU AU2020266139A patent/AU2020266139A1/en active Pending
  • 2020-04-29 CA CA3138856A patent/CA3138856A1/en active Pending
  • 2020-04-29 EP EP20798748.8A patent/EP3962477A4/en active Pending

Patent Citations (2)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events